CHEK2 anticorps (AA 481-531)

N° du produit ABIN1724714

L’anticorps Souris Monoclonal anti-CHEK2 a été validé pour WB, ELISA, IHC et ICC. Il convient pour détecter CHEK2 dans des échantillons de Humain. Il y a 3+ publications disponibles.

Aperçu rapide pour CHEK2 anticorps (AA 481-531) (ABIN1724714)

Antigène: CHEK2 (Checkpoint Kinase 2 (CHEK2))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp CHEK2 est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Immunocytochemistry (ICC)

Clone: 1C12B8

Détail du produit anti-CHEK2 anticorps

Épitope: AA 481-531

Fonction: CHK2 Antibody

Purification: Ascitic fluid

Immunogène: Purified recombinant fragment of human CHK2 (aa481-531) expressed in E. Coli.

Isotype: IgG2b

Information d'application

Indications d'application:

ELISA: 1/10000

ICC: 1/200 - 1/1000

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Ascitic fluid containing 0.03 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

Références pour anticorps anti-CHEK2 (ABIN1724714)

Cybulski, Masojc, Oszutowska, Jaworowska, Grodzki, Waloszczyk, Serwatowski, Pankowski, Huzarski, Byrski, Górski, Jakubowska, Debniak, Wokolorczyk, Gronwald, Tarnowska, Serrano-Fernández, Lubinski et al.: "Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers. ..." dans: Carcinogenesis, Vol. 29, Issue 4, pp. 762-5, (2008) (PubMed).

Antoni, Sodha, Collins, Garrett: "CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?" dans: Nature reviews. Cancer, Vol. 7, Issue 12, pp. 925-36, (2007) (PubMed).

Bell, Kim, Godwin, Schiripo, Harris, Haserlat, Wahrer, Haiman, Daly, Niendorf, Smith, Sgroi, Garber, Olopade, Le Marchand, Henderson, Altshuler, Haber, Freedman: "Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts." dans: International journal of cancer. Journal international du cancer, Vol. 121, Issue 12, pp. 2661-7, (2007) (PubMed).

Détails sur CHEK2

Antigène: CHEK2 (Checkpoint Kinase 2 (CHEK2))

Autre désignation: CHK2

Sujet: CHK2: CHK2 checkpoint homolog (S. pombe). In response to DNA damage and replication blocks, cell cycle progression is halted through the control of critical cell cycle regulators. The protein encoded by this gene is a cell cycle checkpoint regulator and putative tumor suppressor. It contains a forkhead-associated protein interaction domain essential for activation in response to DNA damage and is rapidly phosphorylated in response to replication blocks and DNA damage. When activated, the encoded protein is known to inhibit CDC25C phosphatase, preventing entry into mitosis, and has been shown to stabilize the tumor suppressor protein p53, leading to cell cycle arrest in G1. In addition, this protein interacts with and phosphorylates BRCA1, allowing BRCA1 to restore survival after DNA damage. Mutations in this gene have been linked with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. Also, mutations in this gene are thought to confer a predisposition to sarcomas, breast cancer, and brain tumors. This nuclear protein is a member of the CDS1 subfamily of serine/threonine protein kinases. Three transcript variants encoding different isoforms have been found for this gene.

Poids moléculaire: 61 kDa

UniProt: O96017

Pathways: Signalisation p53, Apoptose, Cycle Cellulaire